Autres langues Sera Prognostics, Inc.

Actions

SERA

US81749D1072

Services d'assistance aux entreprises

Marché Fermé - Nasdaq 22:00:00 22/09/2026			Varia. 5j.	Varia. 1 janv.
2,130 ^USD	+0,47%		+7,04%	-27,80%

19/08	Sera Prognostics nomme Scott Gleason au poste de directeur financier	MT
19/08	Sera Prognostics, Inc. annonce des changements de direction, effectifs au 31 août 2026	CI

Autres langues

21/09	Sera Prognostics, Inc.(NasdaqGM:SERA) dropped from S&P Global BMI Index
19/08	Sera Prognostics Names Scott Gleason as CFO
19/08	Sera Prognostics, Inc. Announces CFO Changes, Effective August 31, 2026
19/08	Sera Prognostics, Inc. Announces Executive Changes, Effective August 31, 2026
19/08	SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
12/08	Sera Prognostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
30/07	SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
09/07	PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
09/07	Sera Prognostics, Inc. Announces Subgroup Analysis Results Demonstrating 22% Reduction in NICU Admissions Using Pretrm Test-Guided Care in First-Time Pregnancies
30/06	Sera Prognostics, Inc. Appoints Mark Capone as Class II Director and Member of Compensation Committee, Effective as of July 1, 2026
30/06	SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
29/06	Sera Prognostics, Inc.(NasdaqGM:SERA) added to Russell Microcap Value Benchmark Index
29/06	Sera Prognostics, Inc.(NasdaqGM:SERA) added to Russell 3000E Value Benchmark
24/06	SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
24/06	Sera Prognostics Participates in Arpa-H Awarded Program to Develop Point-Of-Care Diagnostic Test for Safer Birth
23/06	SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
01/06	SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
01/06	Sera Prognostics, Inc. Announces Jeff Elliott Steps Down from Board of Directors, Effective June 4, 2026
06/05	Sera Prognostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
22/04	SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026
18/03	Sera Prognostics entered into at-the-market sales agreement with William Blair & Company - SEC filing
18/03	Sera Prognostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
18/03	SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS